I usually don't reply to idiots, but I'll make an exception today because you've opened the door for a good point.
The short interest is less than 4% in HEB because the stock is on AMEX and is priced so low; it's hard to find a broker to short it.
If people could short it easier, this stock would be in real trouble. Either way, it's on life support.
The company continues to fall short of its claims, spinning its wheels, making a lot of noise over nothing. On occasion, releasing a press release on data only supported by the company, throwing out vague unfounded potential uses.
The press releases and presentations don't even garner enough attention to move the stock through momentum, so its not even a good trader stock anymore. Maybe those opportunities could return if avian flu catches fire again.
Otherwise, the stock will simply sink a few pennies every few days, until investors are left with the question, 'weren't we supposed to be treating something'?
The company has a long history of a do nothing stock. Nothing going to change. Wake-up, Ampligen isn't good for anything and the FDA isn't going to approve it for anything.
No one including HEB has discovered an effective therapeutic delivery mechanism for dsRNA's. All HEB can talk about is the potential, they have not solved the key problem and the market knows it,everyone but you.